| Alex P Pallas, DO | |
|
4201 W Medical Center Dr, Mchenry, IL 60050-8409 | |
| (815) 334-5566 | |
| (815) 759-4008 |
| Full Name | Alex P Pallas |
|---|---|
| Gender | Male |
| Speciality | Interventional Radiology |
| Experience | 14 Years |
| Location | 4201 W Medical Center Dr, Mchenry, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235455262 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Enloe Medical Center | Chico, CA | Hospital |
| Northwestern Medicine Mchenry Hospital | Mchenry, IL | Hospital |
| Baptist Health Corbin | Corbin, KY | Hospital |
| Palos Community Hospital | Palos heights, IL | Hospital |
| The Medical Center Of Southeast Texas | Port arthur, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southeast Texas Imaging Llp | 3779566906 | 17 |
| Garden City Radiology Pllc | 6406194323 | 3 |
| Dignity Health Medical Foundation | 7810800661 | 1209 |
| Mchenry Radiologists And Imaging Associates Sc | 7810959004 | 29 |
| Enloe Medical Center | 9739092388 | 287 |
| Northwestern Medical Faculty Foundation | 4587576814 | 3255 |
| Radiology And Nuclear Consultants Ltd | 9234114497 | 22 |
| Uintah Basin Medical Center | 0244131944 | 53 |
| Baptist Health Medical Group Inc | 5597867184 | 1912 |
| Garden City Radiology Pllc | 6406194323 | 3 |
News Archive
Using anonymous mobile phone data, Aalto University doctoral researcher Talayeh Aledavood has tapped into patterns in people's behavior. She has found out that our 'chronotypes' - our inherent periods of sleep during a 24-hour-period - correlate with the size of our social networks and how much we are in contact with others and also the kind of chronotypes with whom we interact.
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn't determine where the residual cancer was lurking.
A team of scientists, led by researchers at University of California San Diego School of Medicine, report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer's disease.
› Verified 6 days ago
| Entity Name | Dignity Health Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700803418 PECOS PAC ID: 7810800661 Enrollment ID: O20031107000709 |
News Archive
Using anonymous mobile phone data, Aalto University doctoral researcher Talayeh Aledavood has tapped into patterns in people's behavior. She has found out that our 'chronotypes' - our inherent periods of sleep during a 24-hour-period - correlate with the size of our social networks and how much we are in contact with others and also the kind of chronotypes with whom we interact.
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn't determine where the residual cancer was lurking.
A team of scientists, led by researchers at University of California San Diego School of Medicine, report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer's disease.
› Verified 6 days ago
| Entity Name | Enloe Medical Center |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1477975613 PECOS PAC ID: 9739092388 Enrollment ID: O20140401001696 |
News Archive
Using anonymous mobile phone data, Aalto University doctoral researcher Talayeh Aledavood has tapped into patterns in people's behavior. She has found out that our 'chronotypes' - our inherent periods of sleep during a 24-hour-period - correlate with the size of our social networks and how much we are in contact with others and also the kind of chronotypes with whom we interact.
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn't determine where the residual cancer was lurking.
A team of scientists, led by researchers at University of California San Diego School of Medicine, report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer's disease.
› Verified 6 days ago
| Entity Name | Southeast Texas Imaging Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346205093 PECOS PAC ID: 3779566906 Enrollment ID: O20170906001972 |
News Archive
Using anonymous mobile phone data, Aalto University doctoral researcher Talayeh Aledavood has tapped into patterns in people's behavior. She has found out that our 'chronotypes' - our inherent periods of sleep during a 24-hour-period - correlate with the size of our social networks and how much we are in contact with others and also the kind of chronotypes with whom we interact.
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn't determine where the residual cancer was lurking.
A team of scientists, led by researchers at University of California San Diego School of Medicine, report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer's disease.
› Verified 6 days ago
| Entity Name | Garden City Radiology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336612084 PECOS PAC ID: 6406194323 Enrollment ID: O20190423002573 |
News Archive
Using anonymous mobile phone data, Aalto University doctoral researcher Talayeh Aledavood has tapped into patterns in people's behavior. She has found out that our 'chronotypes' - our inherent periods of sleep during a 24-hour-period - correlate with the size of our social networks and how much we are in contact with others and also the kind of chronotypes with whom we interact.
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn't determine where the residual cancer was lurking.
A team of scientists, led by researchers at University of California San Diego School of Medicine, report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer's disease.
› Verified 6 days ago
| Entity Name | X-ray Professional Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790758449 PECOS PAC ID: 3375539927 Enrollment ID: O20200721000816 |
News Archive
Using anonymous mobile phone data, Aalto University doctoral researcher Talayeh Aledavood has tapped into patterns in people's behavior. She has found out that our 'chronotypes' - our inherent periods of sleep during a 24-hour-period - correlate with the size of our social networks and how much we are in contact with others and also the kind of chronotypes with whom we interact.
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn't determine where the residual cancer was lurking.
A team of scientists, led by researchers at University of California San Diego School of Medicine, report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer's disease.
› Verified 6 days ago
| Entity Name | Mchenry Radiologists And Imaging Associates Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083637094 PECOS PAC ID: 7810959004 Enrollment ID: O20230306000792 |
News Archive
Using anonymous mobile phone data, Aalto University doctoral researcher Talayeh Aledavood has tapped into patterns in people's behavior. She has found out that our 'chronotypes' - our inherent periods of sleep during a 24-hour-period - correlate with the size of our social networks and how much we are in contact with others and also the kind of chronotypes with whom we interact.
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn't determine where the residual cancer was lurking.
A team of scientists, led by researchers at University of California San Diego School of Medicine, report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer's disease.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alex P Pallas, DO 4201 W Medical Center Dr, Mchenry, IL 60050-8409 Ph: (815) 334-5566 | Alex P Pallas, DO 4201 W Medical Center Dr, Mchenry, IL 60050-8409 Ph: (815) 334-5566 |
News Archive
Using anonymous mobile phone data, Aalto University doctoral researcher Talayeh Aledavood has tapped into patterns in people's behavior. She has found out that our 'chronotypes' - our inherent periods of sleep during a 24-hour-period - correlate with the size of our social networks and how much we are in contact with others and also the kind of chronotypes with whom we interact.
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn't determine where the residual cancer was lurking.
A team of scientists, led by researchers at University of California San Diego School of Medicine, report that a class of drugs used for a broad array of conditions, from allergies and colds to hypertension and urinary incontinence, may be associated with an increased risk of cognitive decline, particularly in older adults at greater risk for Alzheimer's disease.
› Verified 6 days ago
Ernest A Conti, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4201 W Medical Center Dr Ste B203, Mchenry, IL 60050 Phone: 815-334-5566 Fax: 815-759-4008 | |
Abhijit Patil, Radiology Medicare: Accepting Medicare Assignments Practice Location: 4201 W Medical Center Dr, Mchenry, IL 60050 Phone: 815-334-5566 Fax: 815-759-4008 | |
Matthew Groenwald, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4201 W Medical Center Dr, Mchenry, IL 60050 Phone: 815-334-5566 Fax: 815-759-4008 | |
James T Link, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3929 Mercy Dr, Mchenry, IL 60050 Phone: 815-759-0800 Fax: 815-759-2367 | |
Milton W Hummel, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3929 Mercy Dr, Mchenry, IL 60050 Phone: 815-759-0800 Fax: 815-759-2367 | |
Dr. Aaron Wittenberg, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4201 W Medical Center Dr, Mchenry, IL 60050 Phone: 815-334-5566 Fax: 815-759-4008 | |
Balatripura Voruganti, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4201 W Medical Center Dr, Mchenry, IL 60050 Phone: 815-334-5566 Fax: 815-759-4008 |